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Abstract
Background: The bone-tumor microenvironment encompasses unique interactions between the
normal cells of the bone and marrow cavity and the malignant cells from a primary or metastasized
cancer. A multitude of paracrine factors within this microenvironment such as the growth factor,
TGF-β, and the chemokine, MCP-1, are secreted by many of these cell types. These factors can act
in concert to modulate normal and malignant cell proliferation, malignant cell migration and
invasion and, often, mediate bone cancer pain. Although many valuable in vitro and in vivo models
exist, identifying the relevant paracrine factors and deciphering their interactions is still a challenge.
The aim of our study is to test an ex vivo coculture model that will allow monitoring of the
expression, release and regulation of paracrine factors during interactions of an intact femur
explant and tumor cells.
Methods:  Intact or marrow-depleted neonatal mouse femurs and select murine and human
sarcoma or carcinoma cell lines were incubated singly or in coculture in specialized well plates.
Viability of the bone and cells was determined by immunohistochemical stains, microscopy and
marrow cytopreps. Secretion and mRNA expression of paracrine factors was quantitated by ELISA
and real-time RT-PCR.
Results: Compartments of the bone were optimally viable for up to 48 h in culture and tumor cells
for up to 4 days. Bone was the major contributor of TGF-β and MMP2 whereas both bone and
sarcoma cells secreted the chemokine MCP-1 in cocultures. Synergistic interaction between the
femur and sarcoma resulted in enhanced MCP-1 secretion and expression in cocultures and was
dependent on the presence of the hematopoietic component of the bone as well as other bone
cells. In contrast, coculturing with breast carcinoma cells resulted in reduction of TGF-β and MCP-
1 secretion from the bone.
Conclusion: These studies illustrate the feasibility of this model to examine paracrine interactions
between intact bone and tumor cells. Further study of unique regulation of MCP-1 secretion and
signaling between these cell types in different types of cancer will be possible using this simulated
microenvironment.
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Background
Cancer is a disease whose outcome is determined by the
malignant tumor cells themselves as well as by the micro-
environment in which they reside. The initial cellular
oncogenic transformation is due to the acquisition or
inheritance of genetic mutations which endows these cells
with a malignant phenotype. The subsequent successful
progression of a tumor also requires favorable tumor-host
interactions. Within the tumor microenvironment, it is
the non-malignant cells, often termed the 'stroma', which
are active and essential components that are recruited and
exploited by malignant cells to ensure tumor survival and
growth [1]. This is also true during metastasis when inva-
sive malignant cells must colonize a 'foreign' microenvi-
ronment and establish a secondary metastatic tumor [2].
It is the paracrine factors of this reactive stroma which
direct the communication between the malignant and
non-malignant cells and therefore are important regula-
tors of this microenvironment.
The bone is a unique and complex microenvironment
that serves as a primary site for sarcomas [3] and as a pref-
erential secondary site for the metastasis of primary carci-
nomas such as breast, prostate and lung cancers [4,5].
Paracrine factors are secreted by or released from many
components of this microenvironment including the
mineralized bone matrix, the major skeletal cells (e.g.
osteoblasts and osteoclasts) and the cells of the bone mar-
row. Through the resorptive activity of osteoclasts, stored
growth factors such as transforming growth factor-β (TGF-
β) and insulin-like growth factor 1 (IGF-1) can be liber-
ated from the bone matrix [6,7]. Both TGF-β and IGF-1
can act as tumor promoters by enhancing proliferation of
malignant cells directly or through the loss of growth inhi-
bition [8-10]. TGF-β is also a profound modulator of the
chemical and structural properties of the bone microenvi-
ronment where it can: 1) support the degradation of the
ECM through activation of matrix metalloproteinases
such as MMP-2 [11,12]; 2) induce angiogenesis [13,14]
and 3) impair immune surveillance and detection of
malignant cells [15,16].
The cells of the bone marrow include hematopoietic stem
cells that give rise to blood cell types such as leukocytes
and erythrocytes as well as adherent stromal cells such as
endothelial cells, fibroblasts, adipocytes and osteogenic
precursors. This component of the bone microenviron-
ment is a rich source of chemokines, cytokines and growth
and angiogenic factors that support the proliferation and
differentiation of these cells [2]. In addition, these factors
also promote tumor development in bone. An example
relevant to our research is the CCβ chemokine, monocyte
chemoattractant protein-1 (MCP-1/CCL2), which was
originally characterized for its role as a promoter of
monocyte/macrophage migration to inflammatory sites
[17] and has been shown to be secreted by endothelial
cells, osteoblasts and osteoclasts within the marrow [18-
20]. MCP-1 can promote monocyte and macrophage infil-
tration into various tumors, similar to its function in
inflammation, potentially creating a path for further inva-
sion [21]. This chemokine also appears to enhance prolif-
eration of prostate cancer cells and promote the migratory
and invasive behavior of prostate as well as breast carcino-
mas [19,22]. Within this microenvironment, it may par-
ticipate in a chemokine-driven vicious cycle where MCP-1
can be secreted by tumor cells which subsequently pro-
motes the secretion of TNF-α as well as other promalig-
nancy factors [1]. Since other cellular components such as
primary afferent sensory nerves also reside in the bone-
tumor microenvironment [23-25], it is interesting to note
that MCP-1 can also directly enhance the excitability of
such nociceptive afferent neurons [26] and, in this way,
might modulate the pain associated with bone metas-
tases.
Deciphering the complexity of interactions between the
cells, their paracrine factors and the downstream signaling
within the bone-tumor microenvironment that promotes
tumor progression and subsequent bone cancer pain con-
tinues to be a challenge. It is accepted that a thorough
understanding of these interactions is important for the
design of future treatment therapies [1]. Therefore, mod-
els that can accurately recapitulate various facets of this
microenvironment and the multi-cellular interactions
present are needed. The current in vivo and in vitro models
have advantages and disadvantages. In vivo models pro-
vide great insight into tumor progression at the whole ani-
mal level but often utilize immunocompromised models
and the accessibility of the microenvironment for sam-
pling and analysis of paracrine factors is limited. In vitro
models usually afford greater ability to manipulate cells
and examine molecular and cellular mechanisms but they
often lack the three-dimensional architecture and the
multiple cell interactions present in the bone-tumor
microenvironment. In the studies presented here, we have
established an in vitro coculture model to monitor the
expression, release and regulation of paracrine factors dur-
ing the interaction of a bone explant and tumor cells. We
show that the bone tissue and a variety of murine and
human carcinoma lines are viable in this culture and each
secrete factors known to be important in tumor survival.
In addition, the interaction of the bone and tumor cells
results in distinct regulation of the chemokine, MCP-1/
CCL2, and is dependent on an 'intact' microenvironment.
Methods
Cell culturing and neonatal femur dissections
Cells
Mouse fibrosarcoma NCTC 2472 (ATCC, Manassas, VA)
were engineered to express Discoma coral-derived red flu-BMC Cancer 2009, 9:45 http://www.biomedcentral.com/1471-2407/9/45
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orescent protein (DsRed2) as previously described [27].
The mouse osteosarcoma K7M2 cells were derived from
the K12 line through in vivo selection resulting in a highly
metastatic line [28] and were provided by Dr. C. Khanna
(National Institutes of Health). The parental MDA-MB-
231 cells and the bone-seeking MDA-MB-231 BO cells
[29] were a gift from Dr. T. Yoneda (University of Texas
Health Sciences). All cells were passaged prior to experi-
ments in bone culture media (BCM) which included α-
MEM supplemented with 10% FBS, 0.2% BSA, 0.3 mg/ml
L-glutamine, 1× NEAA and 1× penicillin-streptomycin
and maintained at 37°C in 5% CO2 water-jacketed incu-
bator. For experiments, cells were acclimated to low
serum conditions by incubation in 5% FBS 24 h prior to
plating for cocultures. An additional antibiotic, gentamy-
cin (50 μg/ml), was added to the media when culturing
bones or co-culturing bones and tumor cell lines. All
media and additional reagents were purchased from Inv-
itrogen (Carlsbad, CA) and Fisher Scientific (Pittsburgh,
PA).
Neonatal femurs
The outbred, immunocompetent CD-1 strain of mice was
used for these experiments (Charles Rivers Laboratories,
Wilmington, MA). Mice were bred and femurs from two-
day postnatal offspring were collected according to proto-
cols approved by the IACUC committee at the University
of Minnesota. Femurs were initially grossly dissected from
the limbs and then placed on PBS-soaked paper towels
under a dissecting scope. Femurs were carefully stripped
of muscles, tendons and loose connective tissue using
fine-tipped forceps and microscissors. Small fragments of
tendons often remained on the condyles and at the epi-
physeal-diaphyseal junction. These fragments were left on
the bones since they were difficult to remove without
damaging the surface of the diaphysis or tearing off pieces
of the condyles (epiphyses). Following dissection, femurs
were immediately placed in serum-free BCM with added
gentamycin and kept in the incubator prior to coculture
setup. Tissues from one neonate were processed in
approximately 15 min and dissected femurs were incu-
bated a maximum of 2 h prior to placement in wellplates
(as described below), which contained BCM without
serum (SF) or with 1% horse serum (1% HS) as appropri-
ate for each experiment. For marrow-depletion experi-
ments, freshly dissected femurs were placed under a
dissecting scope, the condyles were punctured with a 27-
gauge sterile needle and ~500 μl of sterile Dulbecco's
Phosphate Buffered Saline (DPBS) was flushed through
the diaphysis. The clearing of the marrow cavity was veri-
fied by the color change of the effluent (from pink to
clear) and the change in appearance of the diaphysis from
dark red to colorless and translucent. Preliminary tests of
this methodology were followed by histological analysis
of the diaphysis to verify the effectiveness of this proce-
dure in depleting the marrow. Depleted femurs were
immediately place in the appropriate wells to initiate the
experiment.
Coculture set-up
Experiments were conducted in 6-well culture plates
where each well was fitted with a braided, stainless-steel
ring and wire apparatus as shown in Fig. 1. Each apparatus
was made from stainless steel wire wound to form the ring
and wire structure, fitting snugly in each well. These forms
were cleaned, autoclaved and reused as needed. Incuba-
tion of these forms with cells had no effect on the viability
of the tumor cells. All tumor cells were plated in a 35 μl
bead of ~12,000 cells on one side of each well, within the
stainless steel form, and incubated for 2 h to allow for
adherence. After this incubation, 3 mls of the appropriate
BCM was added to each well followed by the placement
of a freshly dissected, single neonatal femur under the
wire of the form. Once completed, plates were incubated
at 37°C in a 5% CO2  water-jacketed incubator and
remained undisturbed until the sampling time points
indicated for each experiment.
Viability assays
Cell counts
The viability of all tumor cells was assessed at time points
indicated by determining total cell number in each well.
Cells were trypsinized, transferred to a hemacytometer
and cell counts taken, with approximately 4 wells sam-
pled at each time point for calculation of the mean total
cell numbers/well and standard error of the means (SEM).
Outer bone layers
To determine the percentage of live cells in the outer layers
of the dissected bones, an average of 3 femurs were col-
lected at each indicated time point and were labeled using
the Live/Dead Viability/Cytotoxicity Kit (Invitrogen/
Molecular Probes) with modifications. Femurs were
washed in 1 × Dulbecco's phosphate buffered saline
(DPBS; w/out Ca2+ or Mg2+) and incubated in a DPBS
solution containing 8 μM ethidium homodimer-1 and 0.8
μM calcein AM for 1 minute in a microwave processor.
Digital images of green fluorescing cells (live cells) and
red fluorescing cells (dead cells) were immediately col-
lected on the ventral surface of the sampled femur,
encompassing ~1/3 of the bone length including the dis-
tal epiphysis and part of the diaphysis with a tissue pene-
tration of ~250 μM. For each femur, a Z-stack of images
was captured at 4× magnification using the MRC 1024
confocal microscope system (Biorad, Hercules, CA) and
cell counts were determined using Image Pro Plus 4.5.1
(Media Cybernetics, Bethesda, MD). The percentage of
live cells was determined by dividing the number of live
cells by the total cell number derived from each Z-stackBMC Cancer 2009, 9:45 http://www.biomedcentral.com/1471-2407/9/45
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and calculating means and standard error of the means
(SEM).
Bone marrow cavity
The in situ determination of marrow viability was per-
formed using the TMR Red In Situ Cell Death Detection
kit (Roche Applied Science; Indianapolis, IN) on sections
of bone tissue. Femurs were collected at each time point,
fixed in 10% neutral buffered formalin for 24 h, decalci-
fied in 10 mM EDTA/PBS pH 6.2 for 14 h, paraffin-
embedded and sectioned (4 μm). Slides were processed
following manufacturer's protocols with positive control
slides treated with 50 μl DNase I (3000 U/ml) for 10 min
prior to processing. Slides were digitally imaged using a
Nikon Eclipse E800M fluorescent microscope. Apoptotic
cell counts from the TMR Red stain were taken from four
400 × 400 pixel fields per bone (2 fields/diaphysis; 2
fields/epiphysis) using Image Pro Plus 4.5.1 and averaged
Characteristics of the bone-tumor cocultures Figure 1
Characteristics of the bone-tumor cocultures. A. Schematic depicting the placement of the physical and biological com-
ponents of the coculture system. The stainless steel ring encircles the outer perimeter of each well in a 6-well plate, with a 
wire protruding from one side into the center (1) that immobilizes a neonatal femur (2). Tumor cells are plated as a bead on 
the opposite side of the well shown as a shaded circle (3). B. Femur is shown in place under the wire with the proximal end (*), 
the distal end (#) and the diaphysis (arrowheads) visible, as well as the dark marrow cavity. C & D. One of the tumor cell lines 
used in the studies, NCTC 2472 fibrosarcoma cells, are pictured as plated, under brightfield (C) as well as under epifluores-
cence (D) showing expression of the DSR protein. Bars shown equal 150 μm.BMC Cancer 2009, 9:45 http://www.biomedcentral.com/1471-2407/9/45
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across each bone. All means and standard error of the
means (SEM) were calculated on an average of 3 femurs
per time point.
Cytopreparations of bone marrow
Bone marrow was extracted from femurs at each time
point as described under the section on neonatal femur
preparation above. Briefly, freshly dissected femurs were
placed under a dissecting scope in a 60 mm dish and the
condyles were punctured with a 27-gauge sterile needle.
Sterile DPBS was flushed through the diaphysis until the
cavity was cleared, as judged by the color and appearance
of the effluent as well as the diaphysis. The extracted mar-
row was passed through a needle to disperse cells, concen-
trated by centrifugation (1500 rpm, 5 min) and
resuspended in 150 μl DPBS. Concentration onto micro-
scope slides was performed (Shandon Southern Cytospin;
1000 rpm, 5 min) followed by staining using the Hema-3
stain set (Fisher Scientific). Images of slides were captured
at 50 & 100× magnification and analysed for cell compo-
sition and integrity of marrow.
Data analysis
For analysis of viability of tumor cell lines, statistical sig-
nificance was determined using ANOVA without match-
ing (P value < 0.05) to determine treatment effect and
Bonferroni post-tests for selected comparisons between
treatments using Prism 4.0 (GraphPad, San Diego, CA).
Enzyme-linked immunosorbent assays (ELISA)
The concentration of the secreted factors in the BCM was
determined using the following Quantikine kits (R&D
Systems, Minneapolis, MN): human/mouse/rat/porcine/
canine TGF-β1, human/mouse total MMP-2 and mouse
JE/MCP-1/CCL-2. Media was collected from an average of
2–3 separate, undisturbed wells at times indicated, centri-
fuged to eliminate cell debris and stored at -80°C. Sam-
ples were assayed in triplicate for these factors following
manufacturer's protocols with minor modifications in
sample dilutions as necessary. Final protein concentra-
tions were averages of triplicate samples corrected for
background media or negative control values. At least
three independent experiments were performed and com-
bined means ± standard error of the means (SE) were cal-
culated. Statistical significance was determined using
ANOVA without matching (P value < 0.05) to determine
treatment effect and Bonferroni post-tests for selected
comparisons between treatments.
Quantitative real-time PCR
To monitor changes in JE/MCP-1/CCL2 expression in the
cocultures, quantitative real-time RT-PCR (Q-PCR) was
used. For RNA extraction from tumor cells collected in
each experiment, 2–3 sets of cells combined from 3–4
duplicate wells were collected at each time point. Cells
were trypsinized, cell suspensions combined and centri-
fuged and pellets stored at -80° for later extraction. For
RNA extraction from bones, 2 sets of bones combined
from 2 duplicate wells were collected at each time point.
Bones were snap frozen in liquid nitrogen and stored at -
80°C. RNA extractions were carried out using the RNeasy
Kit (Qiagen, Valencia, CA) with minor modifications. To
enhance extraction efficiency from bone tissue, individual
bones were ground to a fine powder in liquid nitrogen
using a mortar and pestle prior to processing. All RNA
samples were treated with DNase I using standard proto-
cols (TURBO DNA-free  kit; Ambion). Complementary
DNA was generated from 0.2 μg total RNA using the Taq-
Man reverse transcriptase reagents (ABI, Foster City, CA).
Primers were designed for detection of MCP-1 transcripts
and the endogenous control gene, β-actin using Primer 3
software (MIT; frodo.wi.mit.edu) and were tested using
RT-PCR to verify the production and size of the ampli-
cons. The primer pairs utilized were: (1) mouse MCP-1:
forward – 5'-GAAGGAATGGGTCCAGACAT-3', reverse – 5'-
ACGGGTCAACTTCACATTCA-3'; and (2) mouse β-actin:
forward  – 5'-AGTGTGACGTTGACATCCGTA-3', reverse  –
5'-GCCAGAGCAGTAATCTCCTTCT-3'. Q-PCR reactions
were conducted with SYBR green dye for amplicon detec-
tion using manufacturer's protocol for the Brilliant SYBR
Green QPCR Master Mix kit (Stratagene, La Jolla, CA).
Dissociation curves for each primer set and gel electro-
phoresis analysis of Q-PCR reactions were used to verify a
single amplicon. When possible, multiple lots of cDNA
were tested to insure reproducibility. ΔCt scores for MCP-
1 transcripts in each sample were normalized using ΔCt
scores for β-actin and expressed as the fold change of con-
trol vs. treated using the equation, 2-ΔΔCt. Statistical analy-
sis was performed using Mann-Whitney non-parametric
unpaired t-tests comparing the fold change of each cocul-
tured sample to the fold change value expected if there
was no significant change, that is 0.9–1.20. The P-value
was set to <0.05. At least two replicates of each experiment
were conducted.
Results
Establishment of coculture and component viability
The overall goal of this investigation is to develop a simu-
lated bone-tumor 'microenvironment' to examine para-
crine factors important in bone cancer progression and
pain. The physical set-up of the coculture model was
designed within a well of a 6-well plate where each well
contains a fitted stainless steel ring which encircles the
perimeter of the well and has a wire protruding towards
the center of the well (Fig. 1A, label #1). This wire serves
to immobilize a femur dissected from a day 2 neonate
(Fig. 1A- label #2, B). A femur was chosen as the bone
component since the femur is a major site of bone metas-
tases including the sarcoma cells used in the establish-
ment of this model [30-32]. In addition, unlike adult longBMC Cancer 2009, 9:45 http://www.biomedcentral.com/1471-2407/9/45
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bone fragments or embryonic calvarial explants often
used in other models [33-35], the intact femur retains the
three-dimensional, multi-cell architecture including ossi-
fied bone and hematopoietic cells, stroma and matrix tis-
sue.
Tumor cells were placed directly opposite of the bone near
the edge of the well (Fig. 1A- #3). This location provides
separation of the two biological components and prevents
contamination of either component during culturing. The
NCTC 2472 sarcoma cells were chosen as a fibroblast-like
tumor cell that can form painful osteolytic tumors in
established murine models of bone metastasis and cancer-
induced bone pain [27,30,36,37]. As shown below, we
have also successfully cocultured other types of tumor
cells. These sarcoma cells and all tumor cells were plated
as a bead of media containing ~12,000 cells which results
in a highly confluent area of cells as pictured in Fig. 1C.
Since the sarcoma subclone used in these experiments
expresses the Discoma coral-derived red fluorescent pro-
tein (DsRed2; Fig. 1D), the location of these cells could be
monitored. In addition, since the morphological differ-
ences between tumor cells and sloughed cells from the
femur is very distinct, we were also able to discern the
bone cells from tumor cells. During the culture times
examined, spatial separation of tumor cells and bone was
maintained.
The viability of each biological component, the femur and
the tumor cells, was determined under both serum-free
and low-serum (1% HS) culturing conditions. Serum-free
culturing eliminated the complication of serum factors
and was similar to the normal serum-free conditions in
which bone explants are often cultured. Yet, some tumor
cells require the presence of serum in vitro for optimal
health and proliferation. Therefore, most experiments
were performed under both conditions. Bones or sarcoma
cells were placed as single components in wells as
described above, cultured in serum-free or low-serum
media and the viability of each was tested. To evaluate the
outer cell layers of the femurs, bones were collected just
after dissection (fresh; day 0) and following 2 and 4 days
of culture. These explants were then incubated with cal-
cein green (green-live cells) and ethidium homodimer-1
(red-dead cells) and the number of live and dead cells in
an ~250 μm optical slice was quantified using confocal
microscopy (Fig. 2A, B). The cells labeled within these
outer layers would potentially include: loose collagenous
tissue, pre-osteoblasts and osteoblasts of the periosteum,
chondrocytes within the cartilagenous matrix of the epi-
physes and osteoctyes in the developing osteoid of the
diaphyses. The percentage of live cells labeled ranged
from 89–98% with little change in viability observed
through 4 days of culturing, regardless of the media con-
ditions (Fig. 2C). To assess the interior cells of the femur,
bones were collected at the same timepoints before and
during culturing, processed and stained for the presence
of apoptotic cells within the epiphyses (i.e. condyles,
ends) and the diaphysis (i.e. shaft) of the bone (Fig. 2D,
E). Analysis of sections stained with TMR red labeled
nucleotides revealed a significant increase in the numbers
of apoptotic cells in the diaphysis and marrow cavity after
2 days of culture in either media condition (Fig. 2F). No
change in these numbers was noted at 4 days of culture. In
contrast, little to no apoptotic cells (< 5 cells/field) were
observed in the epiphyses regardless of condition or time
in culture. Bone marrow cytopreparations were also con-
ducted as a qualitative assessment of the viability of the
marrow compartment. Prepared smears of fresh, 24 and
48 hr cultured femurs were examined to determine the
presence and relative predominance of cell types normally
present in this compartment. Marrow isolated from
freshly dissected femurs contained a normal representa-
tion of hematopoietic lineages, no apoptosis or necrosis,
presence of megakaryocytes and the occasional osteob-
lasts and osteoclasts. Cytopreps from 24-hour cultured
femurs revealed increased cell death with the appearance
of necrotic and lysed cells, a shift in granulocytes toward
segmented neutrophils and the occasional osteoblasts
and osteoclasts. After 48 h of culturing, most marrow cells
were apoptotic or necrotic with a large reduction in
mature granulocyte precursors and segmented neu-
trophils. The prevalence and viability of osteoblasts and
osteoclasts appeared to remain constant through 48 h of
culturing. These analyses support the TMR red staining
and suggest that the cells of the marrow compartment, in
contrast to the outer cell layers of the bone and the epi-
physes, are most viable within the first two days of culture.
Therefore, to ensure the potential contribution of all cell
compartments of the bone tissue, experiments to examine
secreted factors in this coculture model were limited to 48
h.
The viability of the sarcoma cells was determined by eval-
uating cell numbers. Cells were plated as described and
cell counts taken on days 0, 2, and 4 of culture. When
compared to initial plating counts, a significant increase
in cell numbers was observed at day 2 for cells alone as
well as cocultures in both serum-free (Fig. 3A) and low
serum media (Fig. 3B). Therefore, these cells are viable
and proliferate under these conditions. In contrast, when
comparing between cells alone and cocultures at this time
point, no significant difference in cell numbers was
observed. This similarity in cell numbers makes it possible
to compare the differences in secreted factors observed in
single component cultures (i.e. cells alone, bone alone)
vs. cocultures based on the interactions between compo-
nents rather than dramatic changes in the number of
tumor cells. Additional increases in cell numbers were
also observed at day 4 with the trend for higher numbersBMC Cancer 2009, 9:45 http://www.biomedcentral.com/1471-2407/9/45
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Viability of femur tissue in culture Figure 2
Viability of femur tissue in culture. A & B. Photomicrograph of femurs freshly dissected (A) or cultured in 1% horse 
serum (HS) for 2 days (B). Images are merged z-stacked slices through ~250 μM of the outer surface of the bone. Scale bars 
equal 0.38 mm (A & B). C. % live (calcein green) cells in femurs cultured in serum free (SF) or 1% horse serum (1% HS) for 0 
days (fresh; white bar), 2 days (gray) and 4 days (black). Data represents an average of 3 femurs per treatment and time point. 
D & E. Photomicrographs of sections taken from freshly dissected femurs assayed for the presence of apoptotic cells (red) 
within the diaphysis and the marrow cavity (D). Adjacent sections (E) were treated with DNase I prior to TMR staining as 
described. Scale bars equal 150 μm. F. Average number of apoptotic cells per field counted within the diaphysis is shown for 
fresh BN sections (white bar) and sections from BN cultured for 2 days (gray) or 4 days (black) in SF or 1% HS media.BMC Cancer 2009, 9:45 http://www.biomedcentral.com/1471-2407/9/45
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in cocultures evident for both serum-free and low serum
media.
Regulation of secreted paracrine factors in cocultures
To characterize the paracrine factors secreted in this model
system, the concentrations of transforming growth factor
β1 (TGF-β1), matrix metalloproteinase 2 (MMP2) and
monocyte chemoattractant protein-1 (MCP-1) were deter-
mined in the media of single component cultures and coc-
ultures. Analysis of TGF-β1 revealed that both the cells
and the bone secrete or release this protein, with the con-
centrations observed in bone alone cultures ~16–18 fold
greater than cells alone in either media (Fig. 4A; P <
0.001). Therefore, the bone appears to be the major con-
tributor of TGF-β1 to this coculture. In addition, no signif-
icant difference was observed in TGF-β1 concentrations
between bone alone and bone-sarcoma cocultures. This
suggests that there are no interaction effects between the
sarcoma cells and the bone regulating TGF-β1 secretion in
these cocultures. Analysis of MMP-2 protein revealed that
MMP2 concentrations were low (1% HS) to nondetecta-
ble (SF) in the cell alone cultures so, as observed for
TGFβ1, the bone is also the major contributor of MMP2 to
the cocultures (Fig. 4B;P < 0.001). Like TGF-β1, no signif-
icant difference between MMP2 concentrations of bone
alone and cocultures is observed therefore there appears
to be no interaction between the components that influ-
ences MMP2 secretion.
In contrast to these factors, the analysis of MCP-1 concen-
trations indicated a strong interaction between coculture
components. An enhancement of MCP-1 secretion was
observed in all femur-sarcoma cocultures (Co-Cult) as
compared to each of the single component cultures,
regardless of serum conditions or day of culture (Fig. 5A;
P < 0.001). Interestingly, the concentration of MCP-1 in
these cocultures at day 2 (SF 8115 ± 564; 1% HS 5165 ±
235 pg/ml) was significantly higher than the simple sum
of the concentration in the single component cultures
(white line on Co-Cult bars in Fig. 5A; BN alone + Cells
alone: SF 3875 ± 295; 1% HS 3559 ± 151 pg/ml). This
potentiation of MCP-1 secretion suggests a synergistic
interaction between the femur and tumor cells in which
the release of specific paracrine factors could result in
enhanced MCP-1 secretion by one or both of these com-
ponents. This was observed as early as day 1 in serum-free
cocultures (dashed line on Co-Cult bar in Fig. 5A; left
graph) and, by day 2, a 1.5–2.1 fold increase in MCP-1
was observed in both media cocultures over the simple
sum of sarcoma cells and bone alone (Fig. 5A; P < 0.001).
Note that no difference was observed in sarcoma cell
numbers in cocultures as compared to single components
cultures through day 2 (see Fig. 3A), therefore the strong
and significant potentiation observed, especially under SF
conditions, cannot be explained by a change in cell
number.
To ensure that this observed synergy was not simply a
result of the culturing conditions, we cultured another
MCP-1 secreting malignant cell line, the K7M2 mouse
osteosarcoma cells, with and without femurs. These cells
are invasive and highly tumorigenic and can function in
Viability of fibrosarcoma cells in culture Figure 3
Viability of fibrosarcoma cells in culture. Viability of mouse NCTC 2472 fibrosarcoma cells cultured alone (Cells) or with 
neonatal femurs (Co-Cult) was determined by cell counts. Cell numbers are shown at initial plating (white bars), day 2 of cul-
ture (gray) and day 4 of culture (black) in serum-free (SF; graph A) and 1% horse serum (HS; graph B) media. Across three 
independent experiments, counts were taken from a total of 5 wells for each time point and media. Day 2 cell counts were 
found to be significantly different from the initial cell counts for both medias. Lowercase letters indicate comparisons between 
cells alone and bone-cell cocultures where (a) above each bar means no significant difference whereas (b) or (c) above each 
bar means a significant difference at P < 0.05 or P < 0.001 respectively.BMC Cancer 2009, 9:45 http://www.biomedcentral.com/1471-2407/9/45
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the bone microenvironment as both a primary and meta-
static tumor [28]. These cells were viable (data not shown)
and secrete MCP-1 in both serum-free and 1% HS condi-
tions (Fig. 5B). Like the sarcoma cells, a significantly
greater concentration of MCP-1 was observed in cocul-
tures of both serum conditions when compared to single
component concentrations (P < 0.01). But, in contrast to
the sarcoma cells, no greater-than-additive effect on MCP-
1 secretion was observed. The concentration of MCP-1 in
the cocultures was not significantly different from the sim-
ple sum of MCP-1 secreted by the single component cul-
tures (dashed line above Co-Cult bars in Fig. 5B; P > 0.05).
The lack of potentiation of MCP-1 secretion in the K7M2
cocultures suggests that no synergistic interaction
occurred between the bone and the osteosarcoma cells.
Therefore, it appears that culturing conditions are not nec-
Secretion of TGFβ1 and MMP2 in cultures Figure 4
Secretion of TGFβ1 and MMP2 in cultures. NCTC 2472 fibrosarcoma cells were cultured alone (Cells), neonatal femurs 
were cultured alone (BN) or these components were cultured together (Co-Cult) and media was collected at indicated times. 
Across four independent experiments, media was sampled from 8–10 wells for each time point, culture condition and media. 
A: Media concentration of transforming growth factor β1 (TGFβ1) at day 1 (white bar) and day 2 (black) are shown for both 
serum-free (left graph) and 1% horse serum (right graph) conditions. Data is graphed as mean pg/ml of TGFβ1 ± SE. B: Media 
concentrations of matrix metalloproteinase 2 (MMP2) at days and media conditions as in A. Data is graphed as mean (× 103) 
pg/ml of MMP2 ± SE. For A & B, significance of statistical comparisons between single-component cultures and cocultures 
where (a) means no significant difference whereas (b) means a significant difference at P < 0.001. Across three independent 
experiments, media was sampled from 5–6 wells for each time point, culture condition and media.BMC Cancer 2009, 9:45 http://www.biomedcentral.com/1471-2407/9/45
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essarily the cause of this synergy. In addition, this regula-
tion of MCP-1 secretion may be unique to the sarcoma
cells.
The interaction between the femur and sarcoma cells also
resulted in enhanced MCP-1 gene expression. Relative
quantitation of MCP-1 transcripts was determined by Q-
PCR using cDNA generated from separate RNA isolates of
femurs and sarcoma cells cultured alone or cocultured in
serum-free conditions. A significant ~1.9 fold increase in
MCP-1 transcripts was observed by day 1 in cocultured
sarcoma cells as compared to those cultured alone (1.94 ±
0.34 (n = 4); P < 0.05; range = 1.88–2.70). Likewise, in day
2 cocultures, sarcoma cells showed an additional
enhancement of MCP-1 expression with an ~3.3 fold
increase in MCP-1 transcript levels (3.25 ± 0.24 (n = 4); P
< 0.05; range = 2.70–3.48). A modest increase in MCP-1
transcript levels was also observed in cocultured femurs
from day 1 cultures (1.31 ± 0.09 (n = 5); P < 0.05; range =
1.11–1.55) but no significant change was observed in day
2 cocultures (0.98 ± 0.08 (n = 5); P > 0.05;range = 0.87–
1.15). This data indicates that both the bone and the
tumor cells upregulate MCP-1 gene expression with the
largest and most consistent upregulation observed in the
Synergistic regulation of MCP-1 in cocultures Figure 5
Synergistic regulation of MCP-1 in cocultures. NCTC 2472 fibrosarcoma (Cells) or mouse osteosarcoma (K7M2) cells 
were cultured alone, neonatal femurs were cultured alone (BN) or these components were cultured together (Co-Cult) and 
media was collected at indicated times. Across four independent experiments, media was sampled from 8–9 wells for each 
time point, culture condition and media. Mean × 103 pg/ml of MCP-1 ± SE is shown for day 1 (white bar) and day 2 (black) of 
culture. A: A greater-than-additive increase in MCP-1 concentration in femur-fibrosarcoma cocultures is observed as com-
pared to cultures of femur or cells alone, regardless of media conditions. Simple sum of [MCP-1]cells + [MCP-1]bn is indicated 
on or above the day 1 Co-Cult bar (dashed line) and on the day 2 Co-Cult bar (white line). Bracket indicates the difference 
between this sum and the actual [MCP-1] observed in cocultures which is statistically significant at P < 0.001(*). B: Cocultures 
conducted with the mouse osteosarcoma K7M2 cells, known to secrete MCP-1 and interact within the bone microenviron-
ment, showed no synergistic regulation of MCP-1 regardless of culture conditions. Simple sum of [MCP-1] cells + [MCP-1]BN 
is indicated above the day 1 and day 2 Co-Cult bars (dashed line).BMC Cancer 2009, 9:45 http://www.biomedcentral.com/1471-2407/9/45
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sarcoma cells. The small increase followed by no change
in bone MCP-1 mRNA may indicate that the cells of the
bone themselves are not as sensitive to the paracrine
effects even though their secretions may modulate the sar-
coma cells. As such, this suggests that the sarcoma cells
may be the major contributor to the enhanced MCP-1
secretion observed in the cocultures. Also, this expression
data provides further support for the conclusion that the
bone and tumor cells interact in this model and are able
to modulate the secretion and gene expression of para-
crine factors from their shared component in coculture.
Relevance of the bone marrow compartment
An important goal of utilizing a femur explant in this
model is to attempt to maintain the multicellular and
multistructural properties of the bone that are known to
be essential for tumor metastasis and growth. The bone
marrow compartment is an excellent microenvironment
within the bone, whose hematopoietic, immune and mes-
enchymal cells secrete many chemokines, cytokines and
growth factors that attract tumor cells and support their
survival. A concern with a whole bone explant is whether
such paracrine factors could diffuse out of the tissue and
actually affect the function of the tumor cells in coculture.
To address this, the marrow cavity of dissected femurs was
flushed with PBS to remove the bone marrow cells and
these marrow-depleted bones were cultured for 24 h alone
or with sarcoma cells. Considering the strong potentiation
of MCP-1 secretion observed under serum-free condi-
tions, experiments were conducted in serum-free media.
The concentration of MCP-1 in culture media was ana-
lyzed and compared to parallel cultures of intact femurs
and their cocultures. Histological examination of intact
vs. depleted bones revealed removal of a majority of the
marrow with little damage to trabecular structure or endo-
steal surfaces (Fig. 6A). Marrow depletion resulted in a
43% decrease in MCP-1 in bone cultures (BN: 754 ± 107
vs. B-Dplt: 429 ± 60 pg/ml; P < 0.05) as well as a 62%
decrease in cocultures (Fig. 6B left graph; CoC: 2487 ± 236
vs. CoC-Dplt: 959 ± 96 pg/ml; P < 0.001). The enhance-
ment of MCP-1 secretion previously observed in the coc-
ultures as compared to intact femurs alone was retained in
the depleted femur cocultures (Fig 6B; P < 0.001). How-
ever, marrow depletion abolished the potentiation of
MCP-1 secretion. In fact, the MCP-1 concentration in coc-
ultures was actually much lower than the simple sum of
the depleted femur plus sarcoma cells alone (Fig 6B;
dashed line above Co-Dplt bar). This suggests that not
only did marrow depletion eliminate potentiation within
the first 24 hrs, but it also resulted in reduced MCP-1
secretion from the sarcoma cells. At 48 hours, depleted
femurs exhibited a 22% reduction in MCP-1 (BN: 1671 ±
262 vs. B-Dplt: 1308 ± 59 pg/ml; P < 0.05) and cocultures
showed a 37% reduction (Fig. 6B right graph; CoC: 8120
± 564 vs. CoC-Dplt: 5129 ± 294 pg/ml; P < 0.01). These
observations indicate that the potentiation of MCP-1
secretion is present in the 48 hr cocultures but is signifi-
cantly attenuated by marrow depletion. Therefore, regula-
tion of MCP-1 secretion is highly dependent on paracrine
factors contributed by the marrow cells early in the inter-
actions between the femur and the tumor cells. In addi-
tion, other cell compartments of the femur must
contribute during the 48 hr of coculture to maintain the
observed MCP-1 secretion.
Modulation of bone by breast carcinoma cells
The appropriateness of this model for human carcinoma
cells was tested using the parental MDA-MB-231 estrogen
receptor negative breast adenocarcinoma cell line [38]
and a bone-seeking clonal line produced from these cells
known as MDA-MB-231 BO [29]. Both lines showed opti-
mal viability in 1% HS culturing conditions so only this
serum condition was used in subsequent experiments.
Cell numbers revealed that parental and BO lines prolifer-
ated well from initial plating through day 2 and no signif-
icant differences were noted between cultures of cells
alone and cocultures with femurs (Fig 7A). Analysis of
secreted paracrine factors revealed that MMP-2, TGF-β1
and MCP-1 were not detectable in cultures of parental (P)
or bone-seeking (BO) cells alone, but were present in
femur alone cultures and cocultures in concentrations
comparable to those observed in sarcoma cultures (Fig.
7B, C, D; also see Fig. 4, 5). The bone tissue was the major
source of these proteins in the breast carcinoma cultures
and, in the case of MMP-2, no significant difference
between single component cultures (cells or femurs
alone) and the cocultures was observed (Fig. 7B). Interest-
ingly, in contrast to MMP-2, secretion of both TGF-β1 and
MCP-1 from the femurs was attenuated in the presence of
the P or BO cells (Fig. 7C, D). MCP-1 secretion was most
dramatically reduced in both P and BO cocultures, with
the highest reductions of 46% observed in the day 1 coc-
ultures of the BO line (P < 0.05) and 44% in day 2 cocul-
tures of the P line (Fig. 7D; P < 0.001) as compared to
cultures of femurs alone. The secretion of TGF-β1 was also
reduced by both tumor lines, with the greatest reductions
observed on day 1 of P cocultures (35%) and BO cocul-
tures (28%; Fig 7C; P < 0.05). These results revealed that
the MDA-MB-231 breast carcinoma cells can modulate
the secretion of paracrine factors from the bone explant.
Discussion
Modeling the unique characteristics of the bone-tumor
microenvironment is an important endeavour for our
understanding of tumor progression and metastasis as
well as the development of bone cancer pain. We have
established a coculture model that simulates many of the
facets of this microenvironment and affords several
advantages. Those advantages include: (1) the mainte-
nance of the complexity and relevance of the bone com-BMC Cancer 2009, 9:45 http://www.biomedcentral.com/1471-2407/9/45
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ponent of this 'microenvironment'; (2) the distinct
separation of the biological components to allow accurate
analyses of each component; and (3) the ease of in vitro
manipulation of all biological components. The bone
component of this model, the intact femur explant,
retains the three-dimensional, multi-cellular architecture
consisting of ossified bone, hematopoietic cells, osteob-
last and osteoclast precursors, stroma and matrix tissue.
Our analyses suggest that the femur is viable in these cul-
tures and is capable of active and regulatable secretion of
important paracrine factors. The cells of the marrow cavity
encased in the diaphysis of this tissue are important con-
Marrow depletion attenuates MCP-1 secretion and coculture synergy Figure 6
Marrow depletion attenuates MCP-1 secretion and coculture synergy. A: Photomicrographs of intact and marrow-
depleted femurs used in cocultures (4× magnification). The marrow cavity of freshly dissected femurs was flushed using 1 × 
PBS or left intact and cultured as described. Representative bones were embedded, sectioned and stained with hematoxylin-
eosin. Bar = 0.6 mm. Bracket delineates marrow cavity. B: Mean × 103 pg/ml MCP-1 ± SE for day 1 (left graph) and day 2 (right 
graph) cultures including intact femurs cultured alone (BN), marrow-depleted femurs (B-Dplt), intact femur-fibrosarcoma (Co-
C) and depleted femur-fibrosarcoma (Co-Dplt). Dotted line on Co-C and Co-Dplt bar indicate the simple sum of [MCP-1]cells 
+ [MCP-1]BNintact or [MCP-1]cells + [MCP-1]B-dplt respectively. Value for [MCP-1]cells was equal to that shown in Figure 5 
as experiments were run in parallel. Across three independent experiments, media was sampled from 7–8 wells for each time 
point, culture condition and media. Asterisks (*) indicate statistically significant difference between Co-C and Co-Dplt values at 
P < 0.001.BMC Cancer 2009, 9:45 http://www.biomedcentral.com/1471-2407/9/45
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tributors to this model since loss of this compartment via
marrow depletion attenuates MCP-1 secretion from bone
and abolishes the potentiation due to bone-sarcoma
interactions. This suggests that paracrine factors are
secreted by these marrow cells, interact within this com-
partment and diffuse into the culture to modulate the
tumor cells. Other in vitro models which have been used
to test the influence of secreted bone factors on tumor
growth and survival or the paracrine effects of tumor cells
on bone resorption often employ single cell cultures, cal-
varial bone or long bone fragments, all of which have lit-
tle to no marrow component present [33-35]. It is true
that the bone marrow contribution to this model would
be presumed to be limited to the early interactions of the
bone and tumor since its viability declines after 24 h. Even
with this limitation, a modulation of a paracrine factor
Cocultures of breast carcinoma cells and mouse femurs show changes in MCP-1 secretions Figure 7
Cocultures of breast carcinoma cells and mouse femurs show changes in MCP-1 secretions. The human breast 
adenocarcinoma parental cell line, MDA-MB-231, and the boneseeking subclone known as MDA-MB-231 BO, were cultured 
alone and with mouse femurs. Viability of these cells in culture, as assessed by cell numbers, and analysis of secreted factors 
was conducted as described. Note that no detectable expression of these factors was observed in single cultures of parental or 
bone subclones. A: Cell numbers (× 103) are shown for the parental line (P), the parental-femur coculture (P-CoC), the bone 
subclone (Bo) and the Bo-femur coculture (B-CoC) at the initial plating (gray bar) and day 1 (white) and day 2 (black) of cul-
ture. B-D: Concentration of MMP2 (B), TGFβ1 (C), and MCP-1 (D) is shown for the femur alone (BN) and the cocultures at 
day 1 (white) and day 2 (black) of culture. In C & D, significant differences between concentration of the secreted factors 
observed in BN cultures (a or c) compared to cocultures with parental or bone-specific MDA cells is indicated by a different 
letter above the Co-C bars, with significance at P < 0.01 (b) or P < 0.001 (d). Across three independent experiments, media 
was sampled from 7–8 wells for each time point, culture condition and media.BMC Cancer 2009, 9:45 http://www.biomedcentral.com/1471-2407/9/45
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due to component interactions can be observed and that
modulation is significantly affected within this time frame
by the loss of the bone marrow.
The presence of the femur in cocultures with the sarcoma
cells results in a strong up- regulation of MCP-1 expres-
sion and secretion. Within 24 h, a greater-than-additive
increase in MCP-1 concentrations is observed along with
increased MCP-1 mRNA in both femur and sarcoma cells
and this potentiation is greater in 48 hr cocultures. These
results suggest that paracrine and autocrine regulation of
MCP-1 occurred in the cocultures due to the action of fac-
tors released by the bone, the tumor cells or both compo-
nents. Numerous factors, known to be present in the
bone-tumor microenvironment, have been shown to
induce MCP-1 secretion and gene expression including
MCP-1 itself [39], TGF-β [40,41], tumor necrosis factor-
alpha (TNF-α) [42], parathyroid hormone related peptide
(PTHrP) [39] and various interleukins [43,44]. The mech-
anism for this potentiation and the factors responsible in
our model are currently under investigation.
It is also interesting to note that comparable concentra-
tions of MCP-1 protein secreted by these sarcoma cells in
this model have been observed by our research group in
in vivo mouse models of bone cancer pain. Microper-
fusates collected in situ from tumors generated by these
fibrosarcoma cells contained approximately 4–7 ng/ml
[45] which is a range similar to the 5–8 ng/ml observed in
the 48 hr bone-tumor cocultures. In addition, strong
MCP-1-like immunoreactivity is detected in tumor biopsy
samples [45]. These results suggest that our model can
accurately simulate this microenvironment, recapitulating
the regulation of this chemokine and potentially other
paracrine factors. One future direction for our research is
to expand this coculture model to include neurons disso-
ciated from dorsal root ganglia (DRG). This will allow the
analysis of local chemical mediators contributing to the
production of bone cancer pain which is difficult to con-
duct in in vivo mouse models. Research to date has shown
that DRG neurons express receptors (CC chemokine
receptor 2 and 4) activated by MCP-1 [46], and that lack
of CCR2 receptor can impair inflammatory and neuro-
pathic pain responses [47,48]; all supporting a potential
role for MCP-1 for the unique type of pain elicited at the
site of bone cancers.
In contrast to the upregulation of MCP-1 in the sarcoma
cultures, it was also observed that co-culturing with the
breast carcinoma cells results in a robust reduction in
TGF-β and MCP-1. This suggests that bidirectional com-
munication between the bone and tumor exists in this
model where secretions from the tumor cells can regulate
the release or secretion of paracrine factors from the bone
tissue. The MDA-MB-231 cell lines did not secrete detect-
able protein in the single-component cultures and
human-specific assays did not detect either cytokine in
cocultures. So, it is presumed that both are being actively
secreted from cells within the bone tissue or passively
released by bone resorption during culturing. Transform-
ing growth factor-β is one of the most abundant growth
factors stored within the mineralized bone matrix [6,7]
and some degradation of the cortical surface of the femur
was observed after 48 h of culturing. Passive release of
TGF-β is therefore possible in these cocultures and factors
released by these breast carcinoma cells may be modulat-
ing this process. In contrast, although it can be stored in
secretory granules of endothelial cells prior to active secre-
tion [49], MCP-1 is not known to be stored within the
bone matrix. Therefore, paracrine factor(s) released by the
breast carcinoma cells may regulate the active secretion of
MCP-1 from cells of the femur tissue which could include
osteoblasts, marrow endothelial cells or immune cells
such as monocytes [18-20]. It is interesting that both of
these cytokines are reduced in parallel raising the possibil-
ity that this effect of the femur-carcinoma interactions
could reflect linked regulation. It has been shown that
TGF-β can have growth-inhibitory and apoptotic effects
on normal and malignant cells, including MDA-MB-231
cells [50,51]. In addition, TGF-β can enhance MCP-1
expression and secretion from a variety of cell types
including osteoblasts and immune cells [40,41,52].
Therefore, during the early interactions in the cocultures,
the MDA cells may counter any potential growth inhibi-
tion by suppressing TGF-β secretion. A decrease in TGF-β
in this microenvironment may cause a loss of positive reg-
ulation of MCP-1 secretion, due to direct effects of TGF-β
or through changes in the secretion of other paracrine fac-
tors.
Like all experimental approaches, this simulated model of
the bone-tumor microenvironment has certain limita-
tions that need to be considered. First, it is most applica-
ble for the investigation of early paracrine interactions
between tumor and bone which are not mediated by cell-
cell or cell-matrix interactions. The contribution of the
hematopoietic compartment to this model are limited to
the first 24–48 hr of culture. Also, the tumor and the bone
are isolated from each other. The advantage of this is that
it allows the dissection of short-term, acute responses to
secreted factors in this microenvironment but does not
address the role of such factors with chronic exposure.
Second, the neonatal femurs utilized have a greater
amount of cartilage than would be expected in an adult
femur. This age of femur was chosen to improve the ease
and efficiency of dissection as well as optimize tissue per-
meability. Such a difference in bone explants from adult
bone, where human primary and metastatic cancers most
often reside, is also the case for research conducted on coc-
ultures of neonatal calvaria and breast or prostate carcino-BMC Cancer 2009, 9:45 http://www.biomedcentral.com/1471-2407/9/45
Page 15 of 17
(page number not for citation purposes)
mas [33,34]. Therefore, the assumptions for extrapolation
of such results to the disease process would be similar but
our model would afford a more complex and representa-
tive microenvironment. Finally, as presented here, the
major tissue or cell source of paracrine factors modulated
by the bone-tumor interactions can only be presumed pri-
marily due to the complexity of the bone tissue. But, in
future experiments, this limitation can be eliminated by
the use of tumor cell lines or tissues from transgenic ani-
mal models where the expression of these factors has been
manipulated.
Conclusion
Our research establishes the usefulness of a coculture
model to study the interaction of paracrine factors
between tumor cells and the 'host' cells of the bone micro-
environment. Studies with this model have revealed its
appropriateness in simulating the regulation of the
cytokine MCP-1 in interactions between sarcoma cells and
bone. These interactions result in the enhancement of
MCP-1 secretion which is dependent on the presence and
viability of the bone marrow compartment as well as
other cells of the bone tissue. Other paracrine factors such
as TGF-β and MMP-2 are secreted but are not regulated by
these bone-tumor interactions. The observations with
breast carcinoma cells in these cocultures supports the
applicability of this model for multiple types of tumor
cells. The interaction of these carcinomas with femurs
resulted in the downregulation of both MCP-1 and TGF-β
secretion from bone, revealing distinct patterns of regula-
tion of these factors and 'cross-talk' between these tissues.
This coculture system should provide further insight into
the paracrine interactions between malignant cells and
the bone microenvironment that are involved in the pro-
gression of sarcomas, which are poorly understood, as
well as the metastasis of other cancers.
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